Clinical Trial: Clinical and Developmental Outcomes of Babies Who Became Yellow in the First Month of Life
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational
Official Title: Neonatal, Clinical and Neurodevelopmental Outcome of Neonates Hospitalized for Neonatal Hyperbilirubinemia Reaching Exchange Transfusion Threshold in a Remote Setting Alon
Brief Summary:
The Shoklo Malaria Research Unit (SMRU) provides care to refugees and migrant populations along the Thai-Burma border since 1986. Services include antenatal and birthing care, with 2,500 births per year and Special Care Baby Units (SCBU) set up in 2008; all medical records including clinical and laboratory data are archived. The treatment of neonatal jaundice is based on treatment thresholds adapted from the neonatal jaundice guidelines, published by the Royal College of Obstetricians and Gynaecologists, UK. Total serum bilirubin (SBR) is done at regular intervals to monitor neonatal hyperbilirubinemia (NH) evolution, following SMRU guidelines. The SCBU have been set up to provide intensive care for neonates in a resource constrained setting and don't have equipment for assisted ventilation other than oxygen therapy. Neonates presenting with high serum bilirubin levels and/or clinical signs of acute bilirubin encephalopathy (ABE) cannot receive exchange transfusion on site and have to be referred to the Thai general hospital one hour drive from the clinics; and, for those neonates surviving, there has not been a systematic follow-up of their growth and neurodevelopment.
The study will consist of a matched case-control series and a retrospective review of SCBU charts of neonates with NH reaching exchange transfusion threshold. The SCBU database will be searched for neonates born at ≥ 28 weeks of gestation hospitalized for phototherapy between January 2009 and December 2014; charts will be manually researched to identify study participants which will be classified as NH reaching exchange transfusion threshold (cases) or as NH within moderate threshold (controls). Additionally neurological signs compatible with ABE will be searched in the clinical notes and coded as present/absent. Cases discharged alive from the SCBU will be traced back to evaluate their clinical and
Detailed Summary:
The study will consist of a matched case-control series and a retrospective review of SCBU charts of neonates with NH reaching exchange transfusion threshold.
The SCBU database will be searched for neonates born at ≥ 28 weeks of gestation hospitalized for phototherapy between January 2009 and December 2014. The SCBU charts of these neonates will be manually researched to identify study participants which will be classified as NH reaching exchange transfusion threshold (cases) or as NH within moderate threshold (controls). Additionally neurological signs compatible with ABE that would likely be reported by the clinical staff will be searched in the clinical notes and coded as present/absent; those signs are: sleepiness, irritability, apnea, convulsions, abnormal position/tone, and abnormal cry. Those charts will be included into the cases.
Cases discharged alive from the SCBU will be traced back to evaluate their clinical and neurocognitive long term outcome. Each case will be matched with a moderate NH control from the same clinic, sex, gestational age and season of birth and hospitalized within the same month.
Both will be examined clinically and findings reported on a standardized forms, their visual function will be tested using the Cardiff acuity and contrast cards and their neurocognitive development will be assessed using the Griffiths Mental Development Scales-Extended revised.
Maternal demographics and additional birth variables (i.e. birth asphyxia, type of delivery, breastfeeding) will be extracted from the antenatal care database and added to the selected cases; laboratory results (G6PD deficiency, ABO incompatibility, haematocrit) are stored in the SCBU database and will be retrieved. The general characteri
Sponsor: University of Oxford
Current Primary Outcome:
- Visual Function Scores [ Time Frame: 8 years ]The odds ratio of visual function scores between survivors of NH reaching exchange transfusion threshold and those with moderate NH
- Neurodevelopmental scores [ Time Frame: 8 years ]The odds ratio of neurodevelopmental scores between survivors of NH reaching exchange transfusion threshold and those with moderate NH
- Clinical status [ Time Frame: 8 years ]The clinical status between survivors of NH reaching exchange transfusion threshold and those with moderate NH
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Mortality rate [ Time Frame: 8 years ]The mortality rate among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with ABE [ Time Frame: 8 years ]The proportion of neonates with ABE among those with NH reaching exchange transfusion threshold
- Proportion of neonates with G6PD deficiency [ Time Frame: 8 years ]The proportion of neonates with G6PD deficiency present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with ABO incompatibility [ Time Frame: 8 years ]The proportion of neonates with ABO incompatibility present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with polycythaemia [ Time Frame: 8 years ]The proportion of neonates with polycythaemia present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with birth trauma [ Time Frame: 8 years ]The proportion of neonates with birth trauma present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonatal sepsis [ Time Frame: 8 years ]The proportion of neonatal sepsis present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with prematurity [ Time Frame: 8 years ]Proportion of neonates with prematurity present among neonates with NH reaching exchange transfusion threshold
Original Secondary Outcome:
- Mortality rate [ Time Frame: 8 years ]The mortality rate among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with ABE [ Time Frame: 8 years ]The proportion of neonates with ABE among those with NH reaching exchange transfusion threshold
- Proportion of neonates with G6PD deficiency [ Time Frame: 8 years ]The proportion of neonates with G6PD deficiency present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with ABO incompatibility [ Time Frame: 8 yrars ]The proportion of neonates with ABO incompatibility present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with polycythaemia [ Time Frame: 8 years ]The proportion of neonates with polycythaemia present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with birth trauma [ Time Frame: 8 years ]The proportion of neonates with birth trauma present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonatal sepsis [ Time Frame: 8 years ]The proportion of neonatal sepsis present among neonates with NH reaching exchange transfusion threshold
- Proportion of neonates with prematurity [ Time Frame: 8 years ]Proportion of neonates with prematurity present among neonates with NH reaching exchange transfusion threshold
Information By: University of Oxford
Dates:
Date Received: October 5, 2016
Date Started: October 2016
Date Completion: March 2017
Last Updated: October 11, 2016
Last Verified: October 2016
